Andrew Paul Mazar - Apr 1, 2025 Form 4 Insider Report for ACTUATE THERAPEUTICS, INC. (ACTU)

Role: Chief Operating Officer
Signature: /s/ Paul Lytle, Attorney-in-Fact
Stock symbol: ACTU
Transactions as of: Apr 1, 2025
Transactions value $: $0
Form type: 4
Date filed: 4/2/2025, 01:43 PM
Previous filing: Aug 12, 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACTU	Employee Stock Option (right to buy)	Award	$0	+51K		$0.00	51K	Apr 1, 2025	Common Stock	51K	$6.70	Direct	F1
transaction	ACTU	Employee Stock Option (right to buy)	Award	$0	+110K		$0.00	110K	Apr 1, 2025	Common Stock	110K	$6.70	Direct	F2

Showing 1 to 2 of 2 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Options will vest as to 25% on April 1, 2026 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date.
F2	Options will vest as to 25% on August 14, 2025 with the remaining 75% vesting in equal monthly installments during the 36 months thereafter.